Tag: clinical trials
-
Immunotherapy Biotech Raises $102 Million in IPO
A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering.
-
Trial Planned to Evaluate CTE Blood Test
A clinical trial is planned of a blood test to detect an indicator of chronic traumatic encephalopathy. or CTE. a neurodegenerative disease associated with collision sports.
-
Neuro Device Company to Begin Clinical Trials in Europe
Clinical trials in Europe are set to begin to test a non-invasive device that stimulates nerves and the spinal cord to treat neuromotor disorders.
-
FDA Begins Cancer Product Review Center
The U.S. Food and Drug Administration is reorganizing its review of treatments for cancer into a structure that cuts across its traditional bureaucratic lines.
-
Lilly Acquires Migraine Therapy Company in $960M Deal
Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms.
-
Experimental Drug Shown to Reduce Tourette’s Symptoms
Results from a clinical trial show an experimental drug is effective in reducing the severity of tics in children with Tourette’s syndrome, a neurological disorder.
-
Knowledge Bank Tapped for Precision Cancer Treatments
An international research team devised techniques for analyzing accumulated clinical trial data to help determine precise treatment strategies for people with cancer.
-
Wearable Device Senses Environment for Sight Impaired
A research lab in Finland designed a wearable device using radar to help people with impaired sight sense other people and objects when outdoors.
-
Neurology Drug Signals Shown to Help Tooth Repair
Chemical signals from a drug designed to treat Alzheimer’s disease and other neurological disorders were shown in tests with mice to stimulate stem cells that repair teeth.
-
Ionis Options Cardiac Drugs in $1.5 Billion Deal
Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease.